基于数据驱动的抗精神病药分类新系统
该研究分析27种抗精神病药对42种受体的亲和力(源自3325项体外受体结合研究),用聚类算法将药物分为4组,并用机器学习模型检验分组对临床试验与指南数据中临床效应的预测能力;4组分别对应毒蕈碱受体拮抗、多巴胺D2部分激动加肾上腺素拮抗、5-羟色胺与多巴胺拮抗、多巴胺拮抗,且第1组和第4组疗效优于第2组和第3组。
要点
- 基于受体亲和力的聚类将27种抗精神病药分为4组,各组有独特受体与临床效应指纹。
- 第1组以M2-M5拮抗为主,对应胆碱能与代谢副作用;第4组以多巴胺拮抗为主,对应锥体外系症状与高催乳素血症。
- 第1组和第4组疗效优于第2组和第3组,分组可预测个体药物的样本外临床效应。
核心结论
- 基于受体亲和力的分组不仅反映药物药理学,还能检测有意义的临床差异,可指导治疗并辅助药物开发。
研究设计与样本
- 分析27种抗精神病药对42种受体的亲和力,数据来自3325项体外受体结合研究。
- 采用聚类算法按受体亲和力分组,并用机器学习模型检验分组对根据临床试验与治疗指南数据伞状综述量化的临床效应的预测能力。
主要发现
- 聚类得到4组抗精神病药,各组主要受体亲和力与临床效应指纹分别为:第1组毒蕈碱(M2-M5)受体拮抗(胆碱能与代谢副作用);第2组多巴胺D2部分激动与肾上腺素拮抗(总体副作用负担低);第3组5-羟色胺与多巴胺拮抗(总体副作用负担中等);第4组多巴胺拮抗(锥体外系副作用与高催乳素血症)。
- 第1组和第4组疗效优于第2组和第3组。
- 该分类可预测个体药物的样本外临床效应。
临床怎么用
- 临床可依据受体亲和力分组预判抗精神病药的副作用谱与疗效差异,辅助个体化选药。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Globally, there are more than 25 licensed antipsychotic medications. Antipsychotics are commonly described as either typical or atypical, but this dichotomous classification does not reflect the diversity of their pharmacological and clinical profiles. There is a need for a data-driven antipsychotic classification scheme suitable for clinicians and researchers that maps onto both pharmacological and clinical effects. Receptor affinity provides one starting point for such a scheme. METHODS: We analyzed affinities of 27 antipsychotics for 42 receptors from 3325 in vitro receptor binding studies. We used a clustering algorithm to group antipsychotics based on receptor affinity. Using a machine learning model, we examined the ability of this grouping to predict antipsychotic-induced clinical effects quantified according to an umbrella review of clinical trial and treatment guideline data. RESULTS: Clustering resulted in 4 groups of antipsychotics. The predominant receptor affinity and clinical effect "fingerprints" of these 4 groups were defined as follows: group 1, muscarinic (M2-M5) receptor antagonism (cholinergic and metabolic side effects); group 2, dopamine (D2) partial agonism and adrenergic antagonism (overall low side-effect burden); group 3, serotonergic and dopaminergic antagonism (overall moderate side-effect burden); and group 4, dopaminergic antagonism (extrapyramidal side effects and hyperprolactinemia). Groups 1 and 4 were more efficacious than groups 2 and 3. The classification was shown to predict out-of-sample clinical effects of individual drugs. CONCLUSIONS: A receptor affinity-based grouping not only reflects compound pharmacology but also detects meaningful clinical differences. This approach has the potential to benefit both patients and researchers by guiding treatment and informing drug development.
引用
- McCutcheon RA, Harrison PJ, Howes OD, et al. Data-Driven Taxonomy for Antipsychotic Medication: A New Classification System. Biol Psychiatry. 2023. PMID: 37061079. doi:10.1016/j.biopsych.2023.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。